TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31734820

Group type: EXPERIMENTAL
Intervention: Dotinurad 1 mg for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topiroxostat 80 mg (concomitant use with Dotinurad)
Number of subjects: 12
Study: 31734832

Group type: EXPERIMENTAL
Intervention: RO6839921 (14-120 mg AP)
Number of subjects: 41
Study: 31734899

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 199

Group type: COMPARATOR
Intervention: Reference infliximab
Number of subjects: 199
Study: 31735436

Group type: EXPERIMENTAL
Intervention: DOACs (apixaban, rivaroxaban, dabigatran, edoxaban)
Number of subjects: 434

Group type: COMPARATOR
Intervention: VKAs (warfarin, acenocoumarol)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 434
Study: 31735660

Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: CRB
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: CRB-65
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: DS CRB-65
Number of subjects: 713
Study: 31735691

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 445
Study: 31736826

Group type: EXPERIMENTAL
Intervention: Baby Triple P (BTP) Positive Parenting Program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 49
Study: 31737275

Group type: EXPERIMENTAL
Intervention: 6-week individualized cervicovestibular rehabilitation program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional approach of gradual sub-threshold physical activation (SPA) alone
Number of subjects: 46
Study: 31737860

Group type: EXPERIMENTAL
Intervention: Red beetroot juice (RBJ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PBO + NIT
Number of subjects: 15

Group type: COMPARATOR
Intervention: NF-RBJ
Number of subjects: 15
Study: 31738177

Group type: EXPERIMENTAL
Intervention: Self-reported food frequency questionnaire
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Urine spot sample analysis
Number of subjects: 802
Study: 31738180

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven monitoring solution with automatic alerts
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven monitoring solution
Number of subjects: 25
Study: 31738181

Group type: EXPERIMENTAL
Intervention: Early AKI (defined by an increase in serum creatinine >0.3 mg/dl or urine output <1 ml/kg per hour on postnatal days 2-7)
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: Early AKI
Number of subjects: 2110
Study: 31738425

Group type: EXPERIMENTAL
Intervention: larotrectinib (20 mg/kg twice daily)
Number of subjects: 1
Study: 31738892

Group type: EXPERIMENTAL
Intervention: CO-OP KT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control (not exposed to CO-OP KT)
Number of subjects: 0
Study: 31739088

Group type: EXPERIMENTAL
Intervention: ICU admission (unplanned patients)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: ICU admission (planned patients)
Number of subjects: 1300
Study: 31739232

Group type: EXPERIMENTAL
Intervention: Narcoleptic patients
Number of subjects: 69
Study: 31739771

Group type: EXPERIMENTAL
Intervention: SPG stimulation with real-time optical tracking guidance and comfortable tolerance level selection based on facial physiological markers.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SPG stimulation
Number of subjects: 50
Study: 31739854

Group type: EXPERIMENTAL
Intervention: Sexual minority females
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Heterosexual females
Number of subjects: 1946
Study: 31739856

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Self-reported adherence with MAD
Number of subjects: 59

Group type: COMPARATOR
Intervention: Self-reported adherence with CPAP
Number of subjects: 59
Study: 31740109

Group type: EXPERIMENTAL
Intervention: Adolescent age at onset (AAO)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Young adult age at onset (AAO)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Middle age age at onset (AAO)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: Child age at onset (AAO)
Number of subjects: 3184

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 3184
Study: 31740479

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy in transgender men (TM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy in transgender women (TW)
Number of subjects: 90
Study: 31740981

Group type: EXPERIMENTAL
Intervention: App-based follow-up using EORTC-QLQ-C30 questionnaires
Number of subjects: 29
Study: 31740996

Group type: EXPERIMENTAL
Intervention: Exeter stem
Number of subjects: 2528

Group type: COMPARATOR
Intervention: SP2 stem
Number of subjects: 2528
Study: 31741153

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Extra-corporeal anastomosis (ECA)
Number of subjects: 1225
Study: 31741744

Group type: EXPERIMENTAL
Intervention: Telehealth-adapted Diabetes Prevention Program (DPP)
Number of subjects: 40
Study: 31741746

Group type: EXPERIMENTAL
Intervention: Early in-bed cycling intervention with mechanically ventilated patients in the ICU
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Rehabilitation Practice and Research
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Motivation barriers
Number of subjects: 53
Study: 31741745

Group type: EXPERIMENTAL
Intervention: Usual care and exercise (8 supervised exercise sessions combined with home-based exercise over a 10-week period)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 31741774

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived T cells
Number of subjects: 39

Group type: COMPARATOR
Intervention: Peripheral blood-derived T cells
Number of subjects: 39
Study: 31741786

Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Muscular Group (MG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study: 31742250

Group type: EXPERIMENTAL
Intervention: 10-2 visual field tests
Number of subjects: 180

Group type: COMPARATOR
Intervention: C24-2 visual field tests
Number of subjects: 180
Study: 31742564

Group type: EXPERIMENTAL
Intervention: Lower vitamin D group (<25 ng/ml), n=22
Number of subjects: 43

Group type: COMPARATOR
Intervention: Higher vitamin D group (≥25 ng/ml), n=21
Number of subjects: 43
Study: 31742568

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of neck anatomy
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ultrasound distances measured (including DSHB)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment
Number of subjects: 194
Study: 31743993

Group type: EXPERIMENTAL
Intervention: Nasal Chondrocytes (NC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Debrided Knee Chondrocytes (dKC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Debrided Knee Chondrocytes (dKC) with TGFβ1 supplementation
Number of subjects: 13
Study: 31744224

Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue (OT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryopreservation of testicular tissue (TT)
Number of subjects: 0
Study: 31744489

Group type: EXPERIMENTAL
Intervention: COBPeer tool
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual peer-review process
Number of subjects: 119
Study: 31744781

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Bupropion monotherapy
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) mono-class therapy
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Bupropion and SSRI combinations
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Antipsychotic-containing regimens
Number of subjects: 565253

Group type: EXPERIMENTAL
Intervention: Multi-class polypharmacy
Number of subjects: 565253

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 565253
Study: 31744867

Group type: EXPERIMENTAL
Intervention: Swallowing assessment (9 criteria evaluated by a physiotherapist)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Presence of one or both gag reflexes
Number of subjects: 159

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 159
Study: 31744891

Group type: EXPERIMENTAL
Intervention: Metabolic and bariatric surgery (MBS)
Number of subjects: 242
Study: 31744895

Group type: EXPERIMENTAL
Intervention: ERK Inhibitor LY3214996
Number of subjects: 0
Study: 31745384

Group type: EXPERIMENTAL
Intervention: Serum biomarkers for predicting outcomes in children with DCM and HCM
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: New onset DCM cohort
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Chronic DCM or HCM cohort
Number of subjects: 288
Study: 31745699

Group type: EXPERIMENTAL
Intervention: Pioglitazone (10, 45, and 90 days duration)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3
Study: 31745703

Group type: EXPERIMENTAL
Intervention: buparlisib and olaparib
Number of subjects: 18
Study: 31745902

Group type: EXPERIMENTAL
Intervention: Interstage renal impairment (RI)
Number of subjects: 705

Group type: COMPARATOR
Intervention: No interstage renal impairment (RI)
Number of subjects: 705
Study: 31746632

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study: 31746688

Group type: EXPERIMENTAL
Intervention: CT angiography with CT perfusion imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA) and SPECT
Number of subjects: 0
Study: 31746765

Group type: EXPERIMENTAL
Intervention: Gamification interventions with social incentives
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 361
Study: 31747004

Group type: EXPERIMENTAL
Intervention: Non-anticoagulated patients with non-paroxysmal AF patterns
Number of subjects: 29181

Group type: EXPERIMENTAL
Intervention: Anticoagulated patients with non-paroxysmal AF patterns
Number of subjects: 29181

Group type: COMPARATOR
Intervention: Non-anticoagulated patients with paroxysmal AF patterns
Number of subjects: 29181

Group type: COMPARATOR
Intervention: Anticoagulated patients with all AF patterns
Number of subjects: 29181
Study: 31747668

Group type: EXPERIMENTAL
Intervention: Binge eaters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Snack eaters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sweet eaters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Healthy eating habits
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall eating patterns
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Weight loss (ΔBMI)
Number of subjects: 300
Study: 31747879

Group type: EXPERIMENTAL
Intervention: Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms (PREVENT) quality improvement intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation activities of the PREVENT intervention
Number of subjects: 0
Study: 31747885

Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 8p lymph nodes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 12b lymph nodes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 12p lymph nodes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 13 lymph nodes
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 14v lymph nodes
Number of subjects: 128
Study: 31748196

Group type: EXPERIMENTAL
Intervention: CRT-defibrillator devices (74.3% of subjects), mainly quadripolar LV leads (75%) deployed laterally (78%)
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Site-defined nonresponders
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Site-defined responders
Number of subjects: 1524
Study: 31748220

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31748235

Group type: EXPERIMENTAL
Intervention: Positive troponin result (higher than the upper limit of normal)
Number of subjects: 257948

Group type: EXPERIMENTAL
Intervention: Positive troponin result
Number of subjects: 257948

Group type: EXPERIMENTAL
Intervention: Troponin level in patients without acute coronary syndrome (ACS)
Number of subjects: 257948

Group type: EXPERIMENTAL
Intervention: Troponin level in patients with ACS
Number of subjects: 257948

Group type: EXPERIMENTAL
Intervention: Troponin level in patients managed invasively with ACS
Number of subjects: 257948

Group type: EXPERIMENTAL
Intervention: Troponin level in patients managed non-invasively with ACS
Number of subjects: 257948
Study: 31748245

Group type: EXPERIMENTAL
Intervention: Completion of radical hysterectomy or other cervical procedure followed by definitive chemoradiation
Number of subjects: 718

Group type: COMPARATOR
Intervention: Abandonment of planned cervical procedure followed by definitive chemoradiation
Number of subjects: 718
Study: 31748285

Group type: EXPERIMENTAL
Intervention: Increased arterial stiffness in patients with HFpEF (Group D)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal healthy volunteers without major comorbidities (Group A)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patients with hypertension without diabetes (Group B)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patients with hypertension and diabetes (Group C)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patients with heart failure and reduced ejection fraction (Group E)
Number of subjects: 5
Study: 31748293

Group type: EXPERIMENTAL
Intervention: Growth patterns measured by body mass index trajectories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other health trajectories including health behaviours, nutrition, cardiometabolic risk and development
Number of subjects: 0
Study: 31749377

Group type: EXPERIMENTAL
Intervention: Lifestyle behavioral intervention
Number of subjects: 0
Study: 31749387

Group type: EXPERIMENTAL
Intervention: Medical triggering events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-medical triggering events
Number of subjects: 0

Group type: COMPARATOR
Intervention: No triggering events
Number of subjects: 0
Study: 31749608

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa enzyme replacement therapy (ERT)
Number of subjects: 152
Study: 31749731

Group type: EXPERIMENTAL
Intervention: Mindfulness-based behavioral intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study: 31749854

Group type: EXPERIMENTAL
Intervention: Diffusing alpha emitters radiation therapy (DaRT) applied to one lesion.
Number of subjects: 1
Study: 31749981

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 31
Study: 31750307

Group type: EXPERIMENTAL
Intervention: Three different exercise strategies, details on dosage and duration not available
Number of subjects: 0
Study: 31750396

Group type: EXPERIMENTAL
Intervention: ranibizumab 0.3 mg
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Number of subjects: 759

Group type: COMPARATOR
Intervention: sham treatment (crossover to ranibizumab 0.5 mg at month 24)
Number of subjects: 759
Study: 31750837

Group type: EXPERIMENTAL
Intervention: Tailored self-help mobile app (Recovery Record)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Standard self-monitoring app (cognitive behavioral therapy-based)
Number of subjects: 959
Study: 31750899

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1753

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1753
Study: 31750988

Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI findings
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Model incorporating clinical variables
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Quantitative DWI-based score
Number of subjects: 499
Study: 31751853

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg subcutaneously (SC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31751906

Group type: EXPERIMENTAL
Intervention: Automatic scoring of cardiorespiratory polygraphy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Manual scoring of cardiorespiratory polygraphy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Oxygen desaturation 4% index (ODI4)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Lowest saturation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Percent of time spent <90% saturation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Respiratory event index (REI)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Obstructive apnea index
Number of subjects: 204
Study: 31752504

Group type: EXPERIMENTAL
Intervention: Extended follow-up intervals for INR monitoring, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard follow-up intervals for INR monitoring, specific dosage and duration not available
Number of subjects: 0
Study: 31752709

Group type: EXPERIMENTAL
Intervention: Educational intervention of palliative care principles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nursing home care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Person-centred care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increased knowledge and education regarding palliative care
Number of subjects: 40
Study: 31752726

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic factors (metabolic control, HbA1c, lipid profile, cholesterol, etc.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OCTA-derived parameters
Number of subjects: 0
Study: 31752752

Group type: EXPERIMENTAL
Intervention: Oral metformin at doses up to 3000 mg per day for 3 months
Number of subjects: 49
Study: 31752882

Group type: EXPERIMENTAL
Intervention: Skin carotenoid status (SCS) assessed using resonance Raman spectroscopy (RRS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Skin carotenoid status (SCS) assessed using pressure-mediated reflection spectroscopy (RS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Self-reported vegetable and fruit (VF) intake
Number of subjects: 52
Study: 31752911

Group type: EXPERIMENTAL
Intervention: ReWalk exoskeleton training for 12 weeks
Number of subjects: 12
Study: 31752951

Group type: EXPERIMENTAL
Intervention: Dual-mobility cup and cementless triple-taper femoral stem combination
Number of subjects: 244
Study: 31752976

Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Delay to appropriate antimicrobial treatment
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Combination antimicrobial therapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Prolonged antimicrobial therapy (>7 days)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Mono versus polymicrobial S. maltophilia HAP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Monomicrobial S. maltophilia HAP
Number of subjects: 282
Study: 31753019

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with anti-BTLA antibody
Number of subjects: 254

Group type: COMPARATOR
Intervention: BTLA expression levels in cancerous tissues
Number of subjects: 254
Study: 31753029

Group type: EXPERIMENTAL
Intervention: Atezolizumab (15 mg/kg every 3 weeks for patients < 18 years; 1200 mg every 3 weeks for patients ≥ 18 years)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 87
Study: 31753466

Group type: EXPERIMENTAL
Intervention: Household air cleaners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no household air cleaners)
Number of subjects: 0
Study: 31753773

Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CRY BC-PLTs) transfusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CRY BC-PLTs)
Number of subjects: 5
Study: 31753788

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) program (10 weeks, intensity: 75-85% of heart rate reserve, frequency: 4 times/week, duration: 45 min)
Number of subjects: 35
Study: 31753865

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0
Study: 31753876

Group type: EXPERIMENTAL
Intervention: Specially adapted resistance training intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Move It Or Lose It: community-based exercise intervention
Number of subjects: 0
Study: 31753878

Group type: EXPERIMENTAL
Intervention: Intraoperative Peripheral Perfusion Index (PPI)
Number of subjects: 2300
Study: 31754049

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade
Number of subjects: 0
Study: 31754316

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31755936

Group type: EXPERIMENTAL
Intervention: PLHIV
Number of subjects: 200

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study: 31756197

Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription
Number of subjects: 20
Study: 31756405

Group type: EXPERIMENTAL
Intervention: Adiposity measured via dual-energy x-ray absorptiometry (DXA)
Number of subjects: 0
Study: 31756720

Group type: EXPERIMENTAL
Intervention: Self-efficacy for physical activity (PA)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Parent support for PA
Number of subjects: 114
Study: 31757860

Group type: EXPERIMENTAL
Intervention: Complementary feeding (CF) initiated at <4 months
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Complementary feeding (CF) initiated at ≥6 months
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Complementary feeding (CF) initiated at 4 to <6 months
Number of subjects: 1013
Study: 31758304

Group type: EXPERIMENTAL
Intervention: Segmental resection (SR) for DIE
Number of subjects: 50
Study: 31758430

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 506
Study: 31758517

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0